Bone Care International Announces Appointment of James Caruso as Vice President of Sales.

Business Editors

MIDDLETON, Wis.--(BUSINESS WIRE)--July 30, 2002

Bone Care International, Inc. (NASDAQ:BCII), is pleased to announce that Jim Caruso has been hired as the Vice President of Sales. Mr. Caruso was formerly the Vice President of Sales of the Neuroscience Business Unit of Novartis. His prior appointments included 14 years at Bristol-Myer Squibb, where he achieved senior level sales and marketing roles, including Director of Sales for the west coast and Director of Neuroscience Marketing. More recently he was Vice President of Sales at BASF Pharmaceuticals prior to its acquisition by Abbott.

"Jim brings a wealth of leadership and cross-functional skills in sales, operations, training, managed health care, and marketing to BCI. We are confident that his addition to the current management at Bone Care will be instrumental in the company's growth in sales both short-term and long-term," said Paul Berns, President and CEO of BCI.

Bone Care is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney, or renal disease, and osteoporosis, and other diseases including psoriasis and cancers of the prostate, breast and colon.

This press release contains forward-looking statements. Statements relating to future net sales, costs of sales, other expenses, profitability, financial resources, or products and production schedules, or statements that predict or indicate future events and trends and which do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs as well as assumptions made by and information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known and unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, technical risks associated with the development of new products, regulatory policies in the United States and other countries, reimbursement policies of public and private health care payors, introduction and acceptance of new drug therapies, competition from existing products and from new products or technologies, the failure by the Company to produce anticipated cost savings or improve productivity, the timing and magnitude of capital expenditures and acquisitions, currency exchange risks, economic and market conditions in the United States, Europe and the rest of the world, and other risks associated with the Company's operations. The Company disclaims any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future events or developments.